In summary, hepatic steatosis in MASLD is supported by increased NEFA influx and de novo lipogenesis, with insulin signaling through IRS-1 and SREBP-1c and glucose metabolism-linked activation of ChREBP activation as key regulators. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.